LL-37
Also known as: Human Cathelicidin, hCAP18-derived peptide
Human Cathelicidin | Antimicrobial Peptide
Overview
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses.
Key benefits
- Direct wound healing acceleration
- Broad-spectrum antimicrobial activity
- Activity against resistant bacteria (MRSA, MDRPA)
- Enhanced tissue regeneration
- Immune modulation
- Local antimicrobial protection
Mechanism of action
Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically.
Molecular data
- Type
- Cationic antimicrobial peptide
- Half-life
- Short (rapid proteolytic degradation)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Wound Healing
Immunity
Skin Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.5mg/mL gel/cream | Daily to twice weekly | — |
| — | 1.6mg/mL gel/cream | Daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-150mcg | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated
- Mild injection site reactions (injectable)
- Local irritation at application site (topical)
Contraindications
- Pre-existing hypersensitivity to peptides
- Compromised immune status (relative contraindication)
- Non-sterile wound environments
Monitoring
- Injection site reactions and excessive irritation
- Signs of wound infection
- Allergic reactions or contact dermatitis
- Wound healing progress